SCTX raises $155.5M, starts STX-1150 first-in-human trial
SCTX initiated first-in-human trial for STX-1150, secured $155.5M via IPO/private placement, and received $25M+ in CIRM grants. Q2 2026 net loss narrowed to $6.5M on lower R&D expenses, with funding runway into H1 2029.
Story updates
08:15:14 PM UTC
SquawkNews
Q2 2026 saw a 61% drop in collaboration revenue and a 35% reduction in net loss year-over-year, driven by lower R&D and G&A expenses. The company completed an IPO and private placement in July, raising $140.7M net, extending its cash runway into 2029.Original document: Scribe Therapeutics Inc. [SCT…
Initiated first-in-human trial for STX-1150, secured $155.5M in IPO/private placement, and received $25M+ in CIRM grants.
Q2 2026 net loss narrowed to $6.5M on lower R&D expenses, with funding runway into H1 2029.
Initial clinical data for STX-1150 expected in H1 2027.Original document: Scribe Ther…